Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Biomaterials ; 187: 105-116, 2018 12.
Article in English | MEDLINE | ID: mdl-30312851

ABSTRACT

Magnetic particles can enrich desired cell populations to aid in understanding cell-type functions and mechanisms, diagnosis, and therapy. As cells are heterogeneous in ligand type, location, expression, and density, careful consideration of magnetic particle design for positive isolation is necessary. Antigen-specific immune cells have low frequencies, which has made studying, identifying, and utilizing these cells for therapy a challenge. Here we demonstrate the importance of magnetic particle design based on the biology of T cells. We create magnetic particles which recognize rare antigen-specific T cells and quantitatively investigate important particle properties including size, concentration, ligand density, and ligand choice in enriching these rare cells. We observe competing optima among particle parameters, with 300 nm particles functionalized with a high density of antigen-specific ligand achieving the highest enrichment and recovery of target cells. In enriching and then activating an endogenous response, 300 nm aAPCs generate nearly 65% antigen-specific T cells with at least 450-fold expansion from endogenous precursors and a 5-fold increase in numbers of antigen-specific cells after only seven days. This systematic study of particle properties in magnetic enrichment provides a case study for the engineering design principles of particles for the isolation of rare cells through biological ligands.


Subject(s)
Antigen-Presenting Cells/cytology , Artificial Cells/cytology , CD8-Positive T-Lymphocytes/cytology , Magnetite Nanoparticles/chemistry , Animals , Antibodies, Monoclonal/chemistry , Antigen-Presenting Cells/metabolism , Artificial Cells/chemistry , CD28 Antigens/immunology , CD8-Positive T-Lymphocytes/metabolism , Humans , Ligands , Magnetic Fields , Major Histocompatibility Complex , Mice , Oligopeptides/chemistry , Protein Binding , Protein Multimerization , Receptors, Antigen, T-Cell/metabolism
2.
Nano Lett ; 17(11): 7045-7054, 2017 11 08.
Article in English | MEDLINE | ID: mdl-28994285

ABSTRACT

Particles engineered to engage and interact with cell surface ligands and to modulate cells can be harnessed to explore basic biological questions as well as to devise cellular therapies. Biology has inspired the design of these particles, such as artificial antigen-presenting cells (aAPCs) for use in immunotherapy. While much has been learned about mimicking antigen presenting cell biology, as we decrease the size of aAPCs to the nanometer scale, we need to extend biomimetic design to include considerations of T cell biology-including T-cell receptor (TCR) organization. Here we describe the first quantitative analysis of particle size effect on aAPCs with both Signals 1 and 2 based on T cell biology. We show that aAPCs, larger than 300 nm, activate T cells more efficiently than smaller aAPCs, 50 nm. The 50 nm aAPCs require saturating doses or require artificial magnetic clustering to activate T cells. Increasing ligand density alone on the 50 nm aAPCs did not increase their ability to stimulate CD8+ T cells, confirming the size-dependent phenomenon. These data support the need for multireceptor ligation and activation of T-cell receptor (TCR) nanoclusters of similar sizes to 300 nm aAPCs. Quantitative analysis and modeling of a nanoparticle system provides insight into engineering constraints of aAPCs for T cell immunotherapy applications and offers a case study for other cell-modulating particles.


Subject(s)
Antigen-Presenting Cells/chemistry , Artificial Cells/chemistry , Immunomodulation , Lymphocyte Activation , Nanoparticles/chemistry , Artificial Cells/immunology , Artificial Cells/ultrastructure , Biomimetic Materials/chemistry , Biomimetic Materials/therapeutic use , Biomimetics/methods , CD28 Antigens/immunology , CD8 Antigens/immunology , Humans , Immunotherapy , Ligands , Major Histocompatibility Complex , Nanoparticles/therapeutic use , Nanoparticles/ultrastructure , Neoplasms/therapy , Particle Size , Receptors, Antigen, T-Cell/immunology
SELECTION OF CITATIONS
SEARCH DETAIL